CME accreditations:

Accredited with

- 25 CME-points of ESMO-MORA category 1 by the “European Society of Medical Oncology (ESMO)“.

- 18 CME-points by the “Arbeitsgemeinschaft Internistische Onkologie” (AIO) of the “German Cancer Society” (16 points of “ESMO-MORA” category 1, and 2 CME points of category 2).

- 21 CME-points by the “Ärztekammer Berlin”.

Final Program
http://www.esho.info/esho2006
MR-Controled Hyperthermia
3D Deep Regional Hyperthermia
MR Imaging

The New Generation Designed by BSD

**Performer LRT**

the keystone of Regional Cancer Therapies

- The only CE marked dedicated system
- The only patented hardware and software system conceived to allow a uniform distribution of a rapidly heated chemotherapeutic agent
- All vital parameters (pressure, flow, fluid volume, temperature, hematocrit, oxygen saturation) displayed and recorded for an easy download and elaboration
- Additional software available for a variety of extracorporeal based therapies

**randD friends for life**

RandD Srl - Via Sparta 60 - 40050 Maddalena (MO) Italy
Tel. +39 055 35892/35790 - Fax. +39 055 35891 - Email info@randdtch.com - www.randdtech.com
Medtronic Sales Office +39 02355 39387
Dear Friends and Colleagues,

We have the great pleasure in presenting the final program for the ESHO 2006 Congress. As you will see, the Educational Day on Wednesday May 24 provides a survey of oncological standards in the treatment of important tumor entities presented by pertinent experts. Following each general presentation of a tumor disease, respective specialists will outline the indications and clinical experiences with various types of hyperthermia application.

Among others, the congress will deal with such key topics as hyperthermic chemoperfusion of peritoneal carcinosis, translational research, new technologies and a synopsis of current clinical studies. A selection of oral presentations and posters taken from more than 80 abstracts represents the scientific part of the congress.

Finally, an exciting social event is planned for Friday May 26, offering a boat trip through the historical and modern parts of Berlin with a delicious buffet and some additional surprises.

On behalf of the Organizing Committee and the ESHO

P. Wust, MD
President of the Meeting
May 24th, 2006 - Educational Day

09:00 Welcome address
Wust, Hildebrandt (Berlin, Germany)

Soft Tissue Sarcoma
09:10 Treatment of adult soft tissue sarcomas – “state of the art”
Reichardt (Berlin, Germany)
09:30 Role of regional hyperthermia combined with chemotherapy in the management of soft tissue sarcoma
Issels (Munich, Germany)

Breast/Chest Wall
09:50 Current standards in the treatment of breast cancer
Janni (Munich, Germany)
10:10 The role of hyperthermia in the treatment of breast cancer and its chest wall recurrences
Jones (Durham, NC, USA)
10:30 Coffee break

Ovary/Cervix
11:00 Treatment of ovarian cancer – “state of the art”
Sehouli (Berlin, Germany)
11:20 Current standards in the treatment of cervix cancer
Schneider (Berlin, Germany)
11:40 Hyperthermia in the treatment of cervix cancer
v.d. Zee (Rotterdam, The Netherlands)

Urogenital
12:00 Treatment of prostate cancer – “state of the art”
Böhmer (Berlin, Germany)
12:20 The role of hyperthermia in the treatment of prostate and bladder cancer
Johannsen (Berlin, Germany)
12:40 Lunch break
May 24th, 2006 - Educational Day

**Upper Abdomen**

13:30 Treatment of esophagus cancer - “state of the art”  
**Schumacher** (Berlin, Germany)

13:50 Current standards in the treatment of gastric cancer  
**Thuss-Patience** (Berlin, Germany)

14:10 Treatment of pancreatic cancer - “state of the art”  
**Stieler/Oettle** (Berlin, Germany)

14:30 Thermometry during the thermal ablation of liver neoplasms  
**Moonen** (Bordeaux, France)

14:50 External methods to heat the abdomen  
**Wust** (Berlin, Germany)

15:10 **Coffee break**

**Colorectal**

15:30 Current standards in colorectal surgery  
**Rau** (Berlin, Germany)

15:50 Surgery of liver metastases - “state of the art”  
**Schumacher** (Berlin, Germany)

16:10 Treatment of metastatic colorectal cancer  
**Hildebrandt** (Berlin, Germany)

16:30 Peritoneal carcinomatosis – open and shut case vs. curative treatment  
**Sugarbaker** (Washington, USA)

17:00 - 17:30 **Discussion**

18:00 **ESHO Board Meeting**
May 25th, 2006

Opening Speech

08:30 Introduction and Welcome
Dörken (Berlin), Issels (Munich), Wust (Berlin)
Including a welcome address from Dr. Thomas Flierl, Berlin’s Senator for Science, Research and Culture
In Memoriam of Dionisio González González from the Dutch Deep Hyperthermia Group

Preclinical Research – Invited Speakers

09:00 The biologic rationale for thermal therapy
Dewhirst (Durham)

09:30 Cell death and resistance against conventional anticancer therapy
Daniel (Berlin)

10:00 Heat shock proteins, tumor antigenicity and hyperthermia
Milani (Munich)

10:30 Coffee break

Innovative Technologies – Invited Speakers

11:00 Thermoablation using interstitial techniques
Vogl (Frankfurt)

11:30 Thermosensitive liposomes
Lindner (Munich)

12:00 Thermoablation or hyperthermia with nanofluids
Jordan (Berlin)

12:30 Lunch break

Special Workshop: Peritoneal Carcinomatosis and Hyperthermia

13:30 Current standards and future studies in hyperthermic peritoneal chemoperfusion
Sugarbaker (Washington)

13:45 Cytoreductive surgery and intraperitoneal chemotherapy – 16 years experience in Lyon
Gilly (Lyon)

14:00 The role of hyperthermic chemoperfusion in the treatment of peritoneal carcinoma of colorectal cancer
Verwaal (Amsterdam)
May 25th, 2006

14:15 The treatment of peritoneal carcinomatosis from colonic cancer and pseudomyxoma peritonei by cytoreduction and hyperthermic antitumor peritoneal perfusion (HAPP)
De Simone (Florence)

14:30 Noninvasive abdominal part-body hyperthermia using a multi-antenna applicator
Gellermann (Berlin)

14:45 Round-table discussion

15:30 Coffee break

Concomitant Research – Invited Speakers

16:00 Markers of cell cycle and apoptosis as prognostic factors in clinical hyperthermia
Sturm (Berlin)

16:20 The rationale for invasive thermometry
Dahl (Bergen)

16:40 Feasibility and thermometry of regional hyperthermia in children
Wessalowski (Düsseldorf)

Current Controversies and Innovative Technologies - Oral Presentations

17:00 Introduction

17:05 Evaluation of thermal dose concepts in superficial hyperthermia: heatability and effective dose
De Bruijne (Rotterdam)

17:15 Biomedical evaluation of the simultaneous application of radiation and local hyperthermia induced by new microstrip applicator operating at 434 MHz: preliminary results
Osinsky (Kiev)

17:25 Interstitial thermotherapy of prostate cancer using magnetic nanoparticles: results of a phase I trial
Johannsen (Berlin)

17:35 Interstitial radiothermotherapy: technical aspects
Bruggmoser (Freiburg)

17:45 Temperature dependence of T1 relaxation time of new long-circulating thermosensitive liposomes with encapsulated gadodiamide
Wang (Munich)

17:55 Discussion
Clinical Research - Poster Exhibition

09:00 - Poster viewing and discussion

The sole superficial hyperthermia for previously irradiated tumors
Owzarek (Gliwice)

A radiofrequency hyperthermia/interstitial HDR brachytherapy in recurrent cervical and endometrial cancer treatment in previously irradiated field
Piotrkowicz (Warsaw)

Possibilities of interstitial and local hyperthermia in a patient with hypopharynx carcinoma
Spenger (Graz)

Novel thermosensitive non-viral gene delivery vectors in combination with hyperthermia
Zitchenko (Munich)

Radiofrequency (RF) interstitial hyperthermia and interstitial high dose rate brachytherapy (HDR-BT) in the treatment of carcinoma of the prostate with benign prostatic hyperplasia
Puthawala (Long Beach)

Thermoradiotherapy with curative intent – breast, head and neck and prostate tumors
Bicher (Los Angeles)

Hyperthermia associated to chemotherapy with gemcitabine in a case of lung metastasis from a thigh sarcoma
Di Fede (Milano)

Hyperthermia associated to chemotherapy (ELF) in a case of hepatic metastasis due to a gastric carcinoma
Di Fede (Milano)

LAK-therapy with whole body hyperthermia in the management of refractory pediatric malignant tumors
Ismail-Zade (Minsk)

Whole body hyperthermia in patients with breast cancer and painful bone metastases
Herzog (Nidda/Bad Salzhausen)

Promising trends in the development of systemic hyperthermia in multimodality therapy for malignant neoplasms
Fradkin (Minsk)

Whole body hyperthermia in hormone-refractory and metastatic prostate cancer
Herzog (Nidda/Bad Salzhausen)
May 25th, 2006

Innovative Technologies / Varia - Poster Exhibition

10:00 - Poster viewing and discussion
10:00 - 10:30

Complex formation on Mn(II) and DPPGOG in long-circulating thermosensitive liposomes for non-invasive thermometry?
Hossann (Munich)

Effect of poly(ethylene glycol)(PEG) on the stability and opening velocity of thermosensitive liposomes
Hossann (Munich)

Resonance circuit for implant hyperthermia affected by radiofrequency pulse of magnetic resonance imaging unit
Niwa (Yokohama)

Dosimeter of photon radiation for simultaneous hyperthermia, created by microwave radiation, and gamma-therapy
Kramer-Ageev (Moscow)

Applicator Technology and Treatment Planning - Poster Exhibition

16:00 - Poster viewing and discussion
16:00 - 16:30

CFMS-like applicators allowing heating of the tumor simultaneously with its external radiation
Mazokhin (Fryazino)

Randomised study on effect of 3D SAR planning on temperature in target volume during deep hyperthermia treatment in patients with cervical cancer
Franckena (Rotterdam)

Patient positioning in Sigma applicators: transferring the position of the planning model into the treatment situation
Wadepohl (Munich)

3D dose planning system for simultaneous treatment by UHF-hyperthermia and distant beam therapy
Klimanow, Gorlachew (Moscow)
May 25th, 2006

Treatment Planning – Oral Presentations

09:00  Introduction

09:05  An improved blood flow model to simulate EM induced hyperthermia
       Neufeld (Zurich)

09:15  Theoretical comparison of intraluminal heating techniques
       Kok (Amsterdam)

09:25  The impact of input parameters in numerical phase/amplitude
       optimisation for hyperthermia treatment planning
       Kok (Amsterdam)

09:35  A head and neck hyperthermia applicator: theoretical antenna
       array design
       Paulides (Rotterdam)

09:45  Improving locoregional hyperthermia using the AMC-8
       waveguide system with 3-D power control and 3-D hyperthermia
       treatment planning
       Crezee (Amsterdam)

09:55  Numerical model for RF capacitive hyperthermia for brain tumours
       D’Ambrosio (Padua)

10:05  Adaptation of RF-hyperthermia planning by MR-thermometry
       Weihrauch (Berlin)

10:15  3-Dimensional calculation of the temperature distribution during
       thermotherapy with magnetic nanoparticles
       Gneveckow (Berlin)

10:25  Discussion

10:30  Coffee break

Clinical Research – Oral Presentations 1
(Mesenchymal and extraabdominal tumours; whole-body hyperthermia)

11:00  Introduction

11:05  Neoadjuvant chemotherapy +- regional hyperthermia (RHT): Local
       control and progression free survival of 122 pts with high-risk soft
       tissue sarcomas (HR-STS) after previously inadequate surgery
       Issels (Munich)

11:15  Radio-hyperthermo-chemotherapy for malignant fibrous histiocytoma
       Matsushita (Nagoya)
Program – Thursday, May 25th

May 25th, 2006

11:25 Better treatment in metastatic melanoma: hyperthermia combined with systemic chemotherapy and radiotherapy
Rigler (Graz)

11:35 Thermoradiation therapy for advanced oropharyngeal cancer
Kurpeshev (Obninsk)

11:45 Treatment results of neo-adjuvant thermal radiochemotherapy in operable oesophageal cancer
Hulshof (Amsterdam)

11:55 Relation between body size and tumour temperatures during locoregional hyperthermia of oesophageal cancer patients
Van Haaren (Amsterdam)

12:05 Whole body hyperthermia in advanced and refractory childhood cancer
Ismail-Zade (Minsk)

12:15 Whole body hyperthermia combined with ifosfamide and carboplatin in recurrent ovarian carcinoma. A phase I-II study
Schem, Mella (Bergen)

12:25 Discussion

12:30 Lunch break

Applicator Technology, Thermometry and Concomitant Research – Oral Presentations

13:30 Introduction

13:35 Water bolus temperature selection in superficial hyperthermia
Van Rhoon (Rotterdam)

13:45 The effect of water bolus temperature on the efficacy of superficial hyperthermia
Samaras (Thessaloniki)

13:55 Comparison of three different types of waveguide horn applicators
Drizdal (Prague)

14:05 Microwave applicators for local thermotherapy
Vrba (Prague)

14:15 Intraluminal heating devices for treatment of oesophageal tumours
Van Haren (Amsterdam)

The ESHO 2006 is supported by:

Main Sponsors:
BSD Medical Corporation
Dr. Sennewald Medizintechnik GmbH
ETM-MedTherM Beratungsgesellschaft mbH
Siemens AG Medical Solutions

Sponsors:
Amgen GmbH
Celsius42 GmbH
Eckert & Ziegler BEBIG GmbH
Euromedical SRL
General Electric Health Care
Hoffmann-LaRoche AG
Hot Oncotherm GmbH
MagForce Nanotechnologies AG
Medtronic Italy
Merck Pharma GmbH
Pavoni Diffusion SAS
Pfizer Pharma GmbH
Sanofi-Aventis Deutschland GmbH
von Ardenne Medizintechnik

The ESHO 2006 is supported by:

Main Sponsors:
BSD Medical Corporation
Dr. Sennewald Medizintechnik GmbH
ETM-MedTherM Beratungsgesellschaft mbH
Siemens AG Medical Solutions

Sponsors:
Amgen GmbH
Celsius42 GmbH
Eckert & Ziegler BEBIG GmbH
Euromedical SRL
General Electric Health Care
Hoffmann-LaRoche AG
Hot Oncotherm GmbH
MagForce Nanotechnologies AG
Medtronic Italy
Merck Pharma GmbH
Pavoni Diffusion SAS
Pfizer Pharma GmbH
Sanofi-Aventis Deutschland GmbH
von Ardenne Medizintechnik

The ESHO 2006 is supported by:

Main Sponsors:
BSD Medical Corporation
Dr. Sennewald Medizintechnik GmbH
ETM-MedTherM Beratungsgesellschaft mbH
Siemens AG Medical Solutions

Sponsors:
Amgen GmbH
Celsius42 GmbH
Eckert & Ziegler BEBIG GmbH
Euromedical SRL
General Electric Health Care
Hoffmann-LaRoche AG
Hot Oncotherm GmbH
MagForce Nanotechnologies AG
Medtronic Italy
Merck Pharma GmbH
Pavoni Diffusion SAS
Pfizer Pharma GmbH
Sanofi-Aventis Deutschland GmbH
von Ardenne Medizintechnik
May 25th, 2006

14:25 Hyperthermia treatment of deep seated tumours using time reversal cavities
Trefna (Goteborg)

14:35 Twin spiral array MW hyperthermia applicators
Turner (Salt Lake City)

14:45 Experimental evaluation of radiation intensity variations caused by CFMA-like EM applicators
Gelvich (Fryazino)

14:55 The design of a fully integrated regional hyperthermia-3T MRI system for the treatment of pelvic tumours
Lagendijk (Utrecht)

15:05 Evaluation of perfusion changes induced by hyperthermia using DCE-MRI
Ollek (Berlin)

15:15 Flow measurements in the portal vein during part body hyperthermia
Gellermann (Berlin)

15:25 Discussion

15:30 Coffee break

Clinical Research – Oral Presentation 2
(Hyperthermia of the pelvis and abdomen)

16:00 Introduction

16:05 Preoperative trimodality treatment in advanced and recurrent rectal cancer: a phase I study
Maluta (Verona)

16:15 Radiochemotherapy in combination with regional hyperthermia in pre-irradiated patients with recurrent rectal cancer
Milani (Munich)

16:25 Radiotherapy plus hyperthermia in locally advanced prostate cancer
Maluta (Verona)

16:35 Chemoradiation combined with deep regional hyperthermia after transurethral resection for T1-2N0M0 bladder cancer: analysis of acute side effects
Ott (Erlangen)
**Program – Thursday, May 25th**

### May 25th, 2006

**16:45** Hyperthermia - a hope for patients unfit for standard gynecological brachytherapy?

**Piotrkowicz** (Warsaw)

**16:55** Radiotherapy and hyperthermia for primary carcinoma of the vagina

**Van der Zee** (Rotterdam)

**17:05** Comparison of interstitial and intraluminal temperatures during deep hyperthermia

**Fatehi** (Rotterdam)

**17:15** Deep electro-hyperthermia with radiofrequencies combined with thermo-active drugs in patients with liver metastases from colorectal cancer (CRC): a phase II clinical study

**Fiorentini** (Empoli)

**17:25** Hyperthermia as treatment option in hepatocellular carcinoma

**Kohek** (Graz)

**17:35** Gemcitabine+Cisplatin (GEM+CIS) in combination with regional hyperthermia (RHT) in second-line therapy of gemcitabine-refractory metastatic pancreatic cancer

**Tschoep** (Munich)

**17:45** Intraperitoneal Cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma

**Jones** (Durham)

**17:55** Discussion

---

**Program – Saturday, May 27th**

### May 27th, 2006

#### ESHO Award

**09:30** Introduction and Award lecture

ev.: **Maluta** (Verona),

**Felix** (Berlin)

**10:00** Invited lecture: The FDTD method as the most practical tool for hyperthermia planning?

**Sullivan** (Moscow/Idaho)

**10:30** Coffee break

#### Clinical Research – Oral Presentations 3 (Ongoing studies)

**11:00** Cervix Cancer – The Dutch View

**Lutgens** (Maastricht)

**11:15** Cervix cancer – the American view

**Jones** (Durham)

**11:30** Recurrent rectal cancer

**Hildebrandt** (Berlin)

**11:45** Soft-tissue sarcoma

**Issels** (Munich)

**12:00** Part body hyperthermia 1

**Wust** (Berlin)

**12:15** Part body hyperthermia 2

**Issels** (Munich)

**13:30** “Chill out” and Charité campus tour
**Speakers - Educational Day**

**Dirk Böhmer MD, PhD (Ger)**
Director, Department of Radiation Oncology, Charité Campus Mitte, Charité-Universitätsmedizin, 13344 Berlin.

**Bert Hildebrandt MD, PhD (Ger)**
Department of Medical Oncology, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

**Rolf-Dieter Issels MD, PhD (Ger)**
Department of Medical Oncology, Klinikum Großhadern, Ludwig-Maximilians-Universität, 81366 Munich.
President of the "European Society for Hyperthermic Oncology (ESHO)".

**Wolfgang Janni MD, PhD (Ger)**
Department of Gynecology, Ludwig-Maximilians-Universität, 80337 Munich.

**Manfred Johannsen MD, PhD (Ger)**
Department of Urology, Charité Campus Mitte, Charité-Universitätsmedizin, 13344 Berlin.

**Ellen Jones MD, PhD (USA)**
Department of Radiation Oncology, Duke University Medical Center, Durham, N.C. 27710, USA.
President of the Society for Thermal Medicine (STM).

**Chrit Moonen PhD (F)**
Molecular and Functional Imaging, Technological Research Unit, University of Bordeaux 2, 33076 Bordeaux.

**Ulf Neumann MD, PhD (Ger)**
Department of Surgery, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

**Helmut Oettle MD, PhD (Ger)**
Department of Medical Oncology, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

**Beate Rau MD, PhD (Ger)**
Clinic of Surgical Oncology, Campus Berlin Buch, Charité-Universitätsmedizin, 13344 Berlin.

---

**Program – Friday, May 26th**

**May 26th, 2006**

**Clinical Research - Poster Exhibition**

08:30 - 09:00  **Poster viewing and discussion**

- Cell survival data processing with artificial neural networks  
  Kosterev (Moscow)

- Medical diagnostics based on measurement of complex permittivity  
  Zajicek (Prague)

- Technical equipment for research of thermal effects of EM field  
  Vrba (Praha)

- Laser heating of sulphuretted carbon nanoparticles inhibits tumor growth  
  Kogan (Moscow)

- The BH3-only protein NbK/Bik induces apoptosis via an ER signalling pathway  
  Gillesen (Berlin)

- Heat shock increases antigen-specific T cell activation using primary sarcoma cells and cell lines transfected with MVA-hTyr  
  Tschoep (München)
May 26th, 2006

Preclinical Research - Oral Presentations

09:30 Introduction

09:35 Hyperthermic regulation of HIF-1alfa in Macrophages
Jackson (Durham)

09:45 The vascular disrupting agent OXi4503 predominantly enhances mild hyperthermia
Hokland (Aarhus)

09:55 Low-temperature hyperthermia induces the formation of color junctions immediately after irradiation
Bergs (Amsterdam)

10:05 Effects of hyperthermia on the peripheral nervous system. An overview
Haveman (Amsterdam)

10:15 Role of apoptosis and cell cycle control for response and survival of colorectal cancer patients treated with preoperative radiochemotherapy ± hyperthermia
Sturm (Berlin)

10:25 Discussion

10:30 Coffee break

Quality Assurance – Oral Presentations

11:00 Introduction

11:05 Quality assurance procedures for superficial hyperthermia equipment in Amsterdam
Crezee (Amsterdam)

11:15 Why we need new paradigm for hyperthermia
Szasz (Budapest)

11:25 Retrospective clinical study for advanced brain-gliomas by hyperthermia treatment
Sahinbas (Bochum)

11:35 Quality assurance procedures for locoregional hyperthermia equipment in Amsterdam
Van Stam (Amsterdam)

11:45 Comparison of radiographic and histopathological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) in patients with soft tissue sarcomas (STS)
Wang (Munich)

11:55 Discussion
Invited Speakers

Olav Dahl MD, PhD (NO)
Institute of Medicine, Section of Oncology, University of Bergen, Haukeland University Hospital, 5021 Bergen.

Michele De Simone MD (I)
Director, U.O.C. of General Oncological Surgery, Hospital San Guiseppe, 50053 Empoli (Florence).

Peter Daniel MD, PhD (Ger)
Department of Medical Oncology, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

Bernd Dörken MD, PhD (Ger)
Director, Charité Centrum “Tumor Medicine” and Department of Medical Oncology, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

Marc Dewhirst DVM, PhD (USA)
Department of Radiation Oncology, Duke University Medical Center, Durham, N.C. 27710.

Alexander M.M. Eggermont MD (NL)
Department of Surgical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, 3075 EA Rotterdam. President of the “European Organisation of Research and Treatment of Cancer (EORTC)”.

Johanna Gellermann MD (Ger)
Department of Radiation Medicine, Campus Berlin Buch, Charité-Universitätsmedizin, 13344 Berlin.

François Gilly MD, PhD (F)
Department of Thoracic Surgery, Centre hospitalo-universitaire Lyon-Sud, Faculté de medecine Lyon-Sud, Oullins.

Susanne Hengst MD (Ger)
Department of Radiation Medicine, Campus Berlin Buch, Charité-Universitätsmedizin, 13344 Berlin.

Bert Hildebrandt MD (Ger)
Department of Medical Oncology, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

Rolf-Dieter Issels MD, PhD (Ger)
Department of Medical Oncology, Klinikum Großhadern, Ludwig-Maximilians-Universität, 81366 Munich. President of the "European Society for Hyperthermic Oncology (ESHO)".

Ellen Jones MD, PhD (USA)
Department of Radiation Oncology, Duke University Medical Center, Durham, N.C. 27710. President of the Society for Thermal Medicine (STM).

Andreas Jordan PhD (Ger)
MagForce Nanotechnologies AG, c/o Center of Biomedical Nanotechnology (CBN), 14050 Berlin.

Program – Friday, May 26th

May 26th, 2006

Special Lecture

12:00 Network of Core Institutions (NoCI) – Instrument for Translational Research
Eggermont, President of EORTC (Rotterdam)

12:30 - 13:30 Lunch break

13:30 ESHO General Assembly

15:00 “International Journal of Hyperthermia” - Editorial Board Meeting (by invitation only)

19:00 Berlin City Tour by River Boat (with buffet)
Innovative Technologies - Invited Speakers (Continued)

May 26th, 2006

08:30 MR-guided focussed ultrasound
Hengst (Berlin)

Applied Clinical Research

09:00 Satellite Symposium: 16th European BSD Users Meeting
(Part 1)

09:00 Introduction
Gellermann (Berlin)

Hyperthermia Technology

09:10 Recent developments and perspectives
Turner (Salt Lake City)

09:30 Superficial hyperthermia: progress in breast cancer
Jones (Durham)

09:50 Interstitial hyperthermia: overview and clinical experience
Puthawala (Long Beach)

10:10 Treatment planning
Van Rhoon (Rotterdam)

10:30 Coffee break

11:00 Satellite Symposium: 16th European BSD Users Meeting
(Part 2) MR Thermography and Control

11:00 MR thermography – The Duke´s experience
Vujaskovic (Durham)

11:20 MR control and regulation of regional hyperthermia
Gellermann (Berlin)

11:40 Discussion

11:50 Closing remarks
Gellermann (Berlin)

Lars Lindner MD (Ger)
Department of Medical Oncology, Ludwig-Maximilians-Universität, 81366 Munich.

Ludy Lutgens MD (NL)
Maastricht Radiation Therapy and Oncology Clinic, University Hospital Maastricht, 6229 Maastricht.

Valeria Milani MD (Ger)
Department of Medical Oncology, Klinikum Großhadern, Ludwig-Maximilians-Universität, 81366 Munich.

Aime Puthawala MD, PhD (USA)
Department of Radiation Oncology, Todd Cancer Institute, Long Beach Memorial Center, Long Beach, CA 90806.

Isrid Sturm MD (Ger)
Department of Medical Oncology, Campus Virchow Klinikum, Charité-Universitätsmedizin, 13344 Berlin.

Paul H. Sugarbaker MD, PhD (USA)
Director Sugical Oncology, Washington Hospital Center, Washington, DC 20010.

Paul F. Turner MSEE (USA)
BSD Medical Corp., Salt Lake City, UT 84119.

Gerard van Rhoon PhD (NL)
Erasmus MC-Daniel den Hoed Cancer Center, Department of Radiation Oncology, 3008 AE Rotterdam.

Jacob van der Zee MD, PhD (NL)
Erasmus MC-Daniel den Hoed Cancer Center, Department of Radiation Oncology, 3008 AE Rotterdam.

Dennis Sullivan PhD, PE (USA)
Electrical & Computer Engineering, University of Idaho, Moscow, Idaho 83844.

Vic J Verwaal MD PhD (NL)
The Netherlands Cancer Institute, 1066 CX Amsterdam.

Thomas J. Vogl MD, PhD (Ger)
Director, Department of Interventional Radiology, Johann Wolfgang von Goethe-Universität, 60590 Frankfurt.

Zeljko Vujaskovic MD, PhD (USA)
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710.

Rüdiger Wessalowski, MD (Ger)
Department of Pediatric Oncology, Heinrich-Heine-Universität, 40225 Düsseldorf.